Lifeloc Q2 2025 net loss $(394k), revenue -7% YoY; SpinDx beta testing begins, launch expected early 2026

Lifeloc Technologies, Inc

2025-Q2 EPS reported -$0.25 revenue$4,496,410

Net revenue $2.219M, down 7% YoY; net loss $(394k) ($0.14 loss per share) vs $(298k) loss in Q2 2024.
Gross margin stable at 41.7%; R&D spend $623k primarily on SpinDx drug testing platform.
SpinDx beta testing underway for delta-9-THC detection; commercial launch targeted for early 2026.
Company began trading on OTCID tier of OTC Markets effective July 1, 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.